RAP 0.00% 20.5¢ resapp health limited

Ann: ResApp Provides SMARTCOUGH-C-2 Study Update, page-5

  1. 2,574 Posts.
    lightbulb Created with Sketch. 4962
    NICE!

    Announced 6 days earlier than last year and exceeds recruitment numbers over last year's. Very good to hear.

    Independent quality assurance of the cough audio recordings has been performed on-site, as per the study protocol, and a sample of the audio recordings have been reviewed directly by
    ResApp. Both of these reviews will continue throughout the study to ensure that audio quality
    is maintained.

    The above paragraph is very reassuring to hear from me as a large investor with in this company!

    Also this below quote from our CEO Tony Keating is very encouraging:


    “We are very pleased with the recruitment rate to date, which exceeds the rate we achieved this time last year, in part due to this year’s worse-than-normal flu season in the United States,” said Tony Keating, CEO and Managing Director of ResApp. “We also note that the improvements we made in training and processes are yielding high quality audio data and that our efforts to homogenise clinical adjudication practices have been well received by the participating hospitals and the independent clinical adjudication team. We look forward to obtaining solid, representative results from the study in the middle of this calendar year and
    rapidly progressing ResAppDx towards regulatory submission and commercialisation.”

    To date 640 kids recruited!
    Last year there was - "As of the 10th of March, 478 participants have been enrolled" ( source was quoted from last year's first updated paediatric smartcough-C results)

    With all the above procedures in place I believe this time around we should yield positive results...

    Regarding the March rebalance.. This the market would have expected as our market capitalisation was now below the range too be placed within that space...

    Very reassuring and very positive! Based on this we should have encouraging results this time round based on all of the above work by Resapp!
    No margin for error this time!

    Very much now looking forward to the Australian double blinded study results coming out very shortly as the results will be a very close indication of what to expect out of the US smartcough- C study.

    Hope you all have a great day and enjoy the weekend...

    Cheers

    Red bar
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.